Selection and Tolerability of Lu177-DOTATATE PRRT: Assessment of Early Cessation of Planned Treatment Cycles

摘要: P1329Introduction: The introduction of a new cancer therapy brings challenges related to appropriate patient selection to ensure completion of planned treatment courses, particularly when the treatment goal is disease stabilization rather than effecting remission. Our aim is to evaluate patients with inoperable neuroendocrine tumor (NET) intended to be treated with standard regimen to determine the non-completion rate (early cessation of planned treatments cycles).Methods: Internal board review permission was obtained for this retrospective study with waiver of consent. Between June 2018 to November 2021 there were 173 patients eligible for Lu177-DOTATATE therapy based on functional assessment, NET histopathology, Ga68-DOTATATE PET (Krenning 3-4), and laboratory screening. The number of delivered cycles for each patient were recorded. Posology strategies including cycle delay and/or dose …